1Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 2Department of Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, ...

Findings from a phase I/II trial provide clinical proof-of-concept for a first-in-class mRNA-encoded T-cell engager targeting CLDN6 and CD3. Produced in vivo, the bispecific was well tolerated and had ...

Cancer Res (2023) 83 (8_Supplement): LB320. QTX3034 has good solubility, permeability, and moderate protein binding in human plasma. The systemic clearance in rats and dogs was moderate to high, ...

Cancer Res (2024) 84 (6_Supplement): 973. Addition of ENZ or AAP to androgen deprivation therapy (ADT) as first-line treatment for advanced prostate cancer improves survival compared to ADT alone.

*Corresponding Author: Mara H. Sherman, Cancer Biology & Genetics, Memorial Sloan Kettering Cancer Center, 417 East 68th Street, 1261, New York, NY 10065. E-mail: [email protected] ...

Purpose: Cancer-associated fibroblasts (CAFs) are highly heterogeneous in pancreatic ductal adenocarcinoma (PDAC). We previously reported that CAFs can acquire an endothelial phenotype under stress.

The FDA today approved Bayer’s darolutamide (Nubeqa) for metastatic castration-sensitive prostate cancer (mCSPC) with or without chemotherapy. The decision was based on the results of the phase III ...

Radiation Research Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland. *Corresponding Author: Jeffrey C. Buchsbaum, Radiation Research Program, Division of Cancer Treatment ...

Drug companies are pouring billions of dollars into PD-1×VEGF bispecific antibodies, hoping these dual-action drugs can outperform existing immunotherapy and anti-angiogenic combinations in lung ...

A 14-gene molecular assay can help identify patients with lung cancer who could benefit from chemotherapy after surgery, according to results of a study presented at the 2025 American Society of ...

1Department of Population Health Sciences, Weill Cornell Medicine, New York, New York. 2Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York. *Corresponding Author: Kevin ...

Results from the phase III ASCENT-04/KEYNOTE-D19 study indicate that the combination of sacituzumab govitecan, a TROP2 antibody–drug conjugate, with the PD-1 inhibitor pembrolizumab is superior to ...